"Ovarian cancer is often diagnosed at late stages, so chemotherapy is a key part of treatment. Most patients will respond to it at first, but everybody develops chemoresistance. And that's when ovarian cancer becomes deadly," says study author.
Researchers looked at tissue samples from ovarian cancer patients. They separated the cells by type to study the tumor microenvironment in cells and in mice. They also linked their findings back to actual patient outcomes.
Ovarian cancer is typically treated with cisplatin, a platinum-based chemotherapy. The researchers found that fibroblasts blocked platinum. These cells prevented platinum from accumulating in the tumor and protected tumor cells from being killed off by cisplatin. Authors demonstrate that glutathione and cysteine released by fibroblasts contribute to this resistance.
Immune T cells, on the other hand, overruled the protection of the fibroblasts. CD8+ T cells abolish the resistance by altering glutathione and cystine metabolism in fibroblasts. CD8+ T-cell-derived interferon (IFN)γ controls fibroblast glutathione and cysteine through upregulation of gamma-glutamyltransferases and transcriptional repression of system xc− cystine and glutamate antiporter via the JAK/STAT1 pathway.
Thus, presence of stromal fibroblasts and CD8+ T cells is negatively and positively associated with ovarian cancer patient survival, respectively. By boosting the immune T cells, the researchers were able to overcome the chemotherapy resistance in mouse models. They used interferon, a type of small protein, to manipulate the pathways involved in cisplatin.
"T cells are the soldiers of the immune system. We already know that if you have a lot of T cells in a tumor, you have better outcomes. Now we see that the immune system can also impact chemotherapy resistance," says study author.
The researchers suggest that combining chemotherapy with immunotherapy may be effective against ovarian cancer. PD-L1 and PD-1 pathway blockers are FDA-approved treatments in some cancers, although not ovarian cancer.
"We can imagine re-educating the fibroblasts and tumor cells with immune T cells after chemoresistance develops," author says. These findings, reported in Cell, suggest a whole different way of thinking about chemotherapy resistance - and the potential to harness immunotherapy drugs to treat ovarian cancer.
http://labblog.uofmhealth.org/lab-report/immune-cells-help-reverse-chemo-resistance-ovarian-cancer
Latest News
A signaling molecule that potently stimulates hair growth
New pathway for accumulation of age-promoting 'zombie cells'
Protecting the brain from dementia-inducing abnormal protein aggregates
Why many cancer cells need to import fat
Role of nonsense-mediated mRNA decay (NMD) in fragile X-syndrome
Other Top Stories
The Cost of Protein Production
Mechanism of abnormal calcium release in failing heart
Protein conformational changes!
Nuclear Retention of mRNA in Mammalian Tissues
Protein nonenzymatic posttranslational modification in aging
Protocols
Light and electron microscopic imaging of synaptic vesicle endocytosis at mouse hippocampal cultures
FLAMBE: A kinetic fluorescence polarization assay to study activation of monomeric BAX
Single-cell mass spectrometry
A behavioral paradigm for measuring perceptual distances in mice
Rapid detection of an Ebola biomarker with optical microring resonators
Publications
Cough hypersensitivity and chronic cough
Telomeric 8-oxo-guanine drives rapid premature senescence in the absence of telomere shortening
The why and how of adaptive immune responses in ischemic cardiovascular disease
Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's d…
Presentations
Hydrogels in Drug Delivery
Lipids
Cell biology of carbohydrate metabolism
RNA interference (RNAi)
RNA structure and functions
Posters
ASCO-2020-HEALTH SERVICES RESEARCH AND QUALITY IMPROVEMENT
ASCO-2020-HEAD AND NECK CANCER
ASCO-2020-GENITOURINARY CANCER–KIDNEY AND BLADDER
ASCO-2020-GENITOURINARY CANCER–PROSTATE, TESTICULAR, AND PENILE
ASCO-2020-GYNECOLOGIC CANCER